B-cell lymphomas overexpressing the c-Myc oncogene also overexpress most components of the SUMO pathway and are highly sensitive to SUMOylation inhibition (Boulanger et al., 2019). Here, MYC is linked to B-cell non-Hodgkin lymphoma.